TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2567113

Group type: EXPERIMENTAL
Intervention: Dilevalol (200 to 1,600 mg once daily)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Metoprolol (100 to 400 mg once daily)
Number of subjects: 449
Study: 30789583

Group type: EXPERIMENTAL
Intervention: Static stretching (3 sets of 30 seconds)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No stretching (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (3 sets of 30 repetitions)
Number of subjects: 45
Study: 31148411

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: PVS > -4% at baseline
Number of subjects: 459
Study: 28976408

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 145
Study: 26169561

Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 40

Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 40
Study: 23203241

Group type: EXPERIMENTAL
Intervention: Pregabalin, starting at 150 mg/day, increasing to 300 or 450 mg/day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 106
Study: 21352267

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: tolterodine ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: tolterodine ER 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: tolterodine ER
Number of subjects: 0
Study: 19701575

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 101
Study: 17897926

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no verapamil)
Number of subjects: 35
Study: 15129933

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (3 x 10-g doses for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11284061

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9134282

Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) 20 mg t.i.d.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Trapidil
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Trapidil and ISDN
Number of subjects: 95
Study: 7946235

Group type: EXPERIMENTAL
Intervention: Community follow-up programme in psychiatric out-patient clinics
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Guardianship networks operated by non-professional volunteers
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Work therapy stations
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 308
Study: 3284488

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CTZ) 480 mg three times a day for 24 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sulphapyridine 1.25 g a day
Number of subjects: 13
Study: 28557858

Group type: EXPERIMENTAL
Intervention: Combined strength and sprint-training (CT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sprint-training (ST)
Number of subjects: 25
Study: 27779312

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Permanent stimulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stimulation
Number of subjects: 36
Study: 25768057

Group type: EXPERIMENTAL
Intervention: Unilateral sequential endoscopic thoracic sympathectomy (S‐ETS)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Simultaneous bilateral endoscopic thoracic sympathectomy (B‐ETS)
Number of subjects: 407
Study: 23032404

Group type: COMPARATOR
Intervention: Brochure group (control)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 205

Group type: COMPARATOR
Intervention: Normal care group (control)
Number of subjects: 205
Study: 21869698

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 19994560

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM‐SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q‐SRP)
Number of subjects: 20
Study: 17179734

Group type: EXPERIMENTAL
Intervention: AST‐120 co‐administered with ongoing treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ongoing treatments only (control group)
Number of subjects: 43
Study: 16779302

Group type: EXPERIMENTAL
Intervention: Software architecture for simultaneous voice conferencing and remote device control over a single telephone line
Number of subjects: 0
Study: 12411880

Group type: EXPERIMENTAL
Intervention: Orthodontic wax containing benzocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unmedicated orthodontic wax
Number of subjects: 70
Study: 10222447

Group type: EXPERIMENTAL
Intervention: pantoprazole (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: omeprazole MUPS (20 mg)
Number of subjects: 16
Study: 7838902

Group type: EXPERIMENTAL
Intervention: Group I (women with recent weight gain)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Whole sample
Number of subjects: 13
Study: 2331418

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine (10 micrograms) administered alone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine mixed with DTP vaccine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polyribosyl‐ribitol phosphate (PRP) vaccine administered alone
Number of subjects: 76
Study: 395959

Group type: EXPERIMENTAL
Intervention: N‐methyl‐N‐(beta‐hydroxyethyl) guanidine O‐phosphate (creatinol O‐phosphate, COP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference substance (solvent of COP)
Number of subjects: 0
Study: 31360162

Group type: EXPERIMENTAL
Intervention: 6 Hz transcranial alternating current stimulation (tACS) applied to the dorsolateral prefrontal cortex (DLPFC) during Stroop task performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 9.7 Hz tACS (nonharmonic alpha band control)
Number of subjects: 0
Study: 27840069

Group type: EXPERIMENTAL
Intervention: Re-treatment with the same first-line ACT
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Alternative ACT
Number of subjects: 571

Group type: COMPARATOR
Intervention: Quinine-clindamycin (QnC)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Re-treatment with the same ACT
Number of subjects: 571
Study: 24950276

Group type: EXPERIMENTAL
Intervention: Statistical nomograms based on sex, serum albumin, platelet count, microvascular invasion, and calculated tumor volume.
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Statistical nomograms validated in an independent cohort.
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Statistical nomograms compared to conventional staging systems.
Number of subjects: 1085
Study: 24074514

Group type: EXPERIMENTAL
Intervention: Early cognitive screening battery
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Mini Mental Status Examination (MMSE)
Number of subjects: 123
Study: 21775749

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 1791
Study: 19291496

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) using the Modified Teaching Kids to Cope (MTKC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 84
Study: 17091022

Group type: EXPERIMENTAL
Intervention: Medication Managers (MM)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Medication Alarms (ALR)
Number of subjects: 928

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 928
Study: 15303639

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 microg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 11739446

Group type: EXPERIMENTAL
Intervention: 120 mg nateglinide
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 mg glyburide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9432479

Group type: EXPERIMENTAL
Intervention: 30 micrograms synthetic estrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 micrograms synthetic estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (30 and 50 micrograms)
Number of subjects: 0
Study: 8101254

Group type: EXPERIMENTAL
Intervention: Sublingual oestradiol‐17 beta (1 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3305189

Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, cytoxan, and prednisone (VCP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Induction therapy with vincristine, rubidazone, araC, and prednisone (VRAP)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Postremission consolidation using adriamycin, araC, and asparaginase (AAA)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 244
Study: 31709920

Group type: EXPERIMENTAL
Intervention: CBT‐YA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: FT‐YA
Number of subjects: 74
Study: 29248397

Group type: EXPERIMENTAL
Intervention: Low back mobility exercises from Pilates
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low back stability exercises from Pilates
Number of subjects: 28
Study: 27260862

Group type: EXPERIMENTAL
Intervention: Potassium Citrate (Kcitrate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Potassium Chloride (KCl)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25222606

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spontaneous Breathing
Number of subjects: 20
Study: 23439351

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 96
Study: 21477047

Group type: EXPERIMENTAL
Intervention: Reinforcement-based treatment (RBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 89
Study: 18479404

Group type: COMPARATOR
Intervention: Web-based questionnaire (n=271)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil questionnaire (n=261)
Number of subjects: 532
Study: 15858160

Group type: EXPERIMENTAL
Intervention: Activity of the dorsolateral, ventrolateral and medial prefrontal cortices during deception (both types: pretending to know and pretending not to know)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity of the anterior cingulate cortex (ACC) during deception (specifically pretending not to know)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) increase in the ACC
Number of subjects: 0
Study: 12633783

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 10686191

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 273

Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 273
Study: 9315991

Group type: EXPERIMENTAL
Intervention: 7.5 mg quazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 mg quazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5 mg quazepam and 15 mg quazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7680764

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 899

Group type: COMPARATOR
Intervention: MACOP-B
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: m-BACOD
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Fatal toxic reactions
Number of subjects: 899
Study: 3050179

Group type: EXPERIMENTAL
Intervention: Journal club
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control seminar series
Number of subjects: 44
Study: 31907248

Group type: EXPERIMENTAL
Intervention: Clinician-initiated prompt to ask a QOL question: 'What things are you unable to do because of your health problems today?'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with no prompting to ask QOL questions.
Number of subjects: 60
Study: 29303859

Group type: EXPERIMENTAL
Intervention: Bovine bone xenograft granules (0.25 to 1 mm of size, 1 mL/vial) with a resorbable pericardium membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated extraction socket)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 20
Study: 27607865

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study: 25397817

Group type: EXPERIMENTAL
Intervention: MRP+TAU
Number of subjects: 146

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 146
Study: 23719147

Group type: EXPERIMENTAL
Intervention: Pretreatment EEG features
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Shortest seizure duration
Number of subjects: 446
Study: 20962560

Group type: EXPERIMENTAL
Intervention: Lactulose breath test (LBT)
Number of subjects: 76
Study: 19363850

Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide combination
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Background antihypertensive therapies
Number of subjects: 11140
Study: 17203670

Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions (personal care, information, prescription of assistive devices, planning of discharge, reporting to primary care or community care)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No occupational therapy interventions (control group)
Number of subjects: 41
Study: 14601526

Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) in combination with rituximab (Rituxan) for non-Hodgkin's lymphoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) as a vaccine adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) for melanoma
Number of subjects: 0
Study: 10230184

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study: 8953207

Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 1752712

Group type: EXPERIMENTAL
Intervention: Iron supplementation (650 mg ferrous sulfate; 130 mg elemental iron)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 7039147

Group type: EXPERIMENTAL
Intervention: Feprazone 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen 750 mg
Number of subjects: 40
Study: 31093797

Group type: EXPERIMENTAL
Intervention: Mechanical debridement with photobiomodulation (PBM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Mechanical debridement only (control group)
Number of subjects: 19
Study: 28283279

Group type: EXPERIMENTAL
Intervention: T‐ionto CL
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard CL
Number of subjects: 25
Study: 25838001

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Treatment adherence (not using illicit opiates on top of prescribed opiates)
Number of subjects: 23
Study: 23846250

Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant) administration (30 mg/cm height, up to three doses)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant) administration
Number of subjects: 110
Study: 20889533

Group type: EXPERIMENTAL
Intervention: Emotion-focused intervention
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Goal-oriented intervention
Number of subjects: 94
Study: 19228095

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both PDT and SRP
Number of subjects: 10
Study: 17203469

Group type: EXPERIMENTAL
Intervention: Thienopyridine pretreatment with loading dose (group 1)
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Thienopyridine pretreatment without loading dose (group 2)
Number of subjects: 2040

Group type: COMPARATOR
Intervention: No thienopyridine pretreatment (group 3)
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Eptifibatide (GP IIb/IIIa inhibitor)
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Thienopyridine pretreatment with eptifibatide
Number of subjects: 2040
Study: 15013031

Group type: EXPERIMENTAL
Intervention: Flesinoxan
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pindolol (30 mg p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ritanserin (10 mg p.o.)
Number of subjects: 6
Study: 11329832

Group type: EXPERIMENTAL
Intervention: Allocation of positive outcomes
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Withdrawal of negative outcomes
Number of subjects: 57

Group type: COMPARATOR
Intervention: Allocation of negative outcomes
Number of subjects: 57

Group type: COMPARATOR
Intervention: Withdrawal of positive outcomes
Number of subjects: 57
Study: 9141898

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 5 megaunits tiw for 8 weeks, then reduced to 3 megaunits up to 9 months (group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Interferon alfa‐2b, 5 megaunits tiw for 16 weeks, then reduced to 3 megaunits up to 9 months (group B)
Number of subjects: 106
Study: 7950223

Group type: EXPERIMENTAL
Intervention: Jian Pi Ling (JPL) tablet with retention‐enema of Radix Sophorae Flavescentis and Flos Sophora (RSF‐FS) decoction
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: salicylazosulfapyridine (SASP) and retention‐enema of dexamethasone
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo and retention‐enema of decoction as that in group I
Number of subjects: 153
Study: 3035479

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 30
Study: 29542812

Group type: COMPARATOR
Intervention: Mindfulness meditation (MM) practice + control task
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) practice + values clarification (VC) task
Number of subjects: 120
Study: 28634365

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin) in patients with SBP ≥ 140 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin in patients with DBP ≥ 90 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone in patients with SBP < 140 mmHg or DBP < 90 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 0
Study: 26132887

Group type: EXPERIMENTAL
Intervention: Online self-regulation activities (goal-setting and self-monitoring)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated goal-setting and monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated self-monitoring
Number of subjects: 0
Study: 23562341

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA), treated twice a day for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo, treated twice a day for 6 weeks
Number of subjects: 32
Study: 21941046

Group type: EXPERIMENTAL
Intervention: Additional Cash Incentive (ACI) scheme within the CCT scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no ACI scheme)
Number of subjects: 0
Study: 18476292

Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy (ART; drug conservation [DC] group])
Number of subjects: 477

Group type: COMPARATOR
Intervention: Continuous ART (viral suppression [VS] group)
Number of subjects: 477
Study: 16550574

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) combined with hepatic arterial infusion (HAI) chemotherapy (FUDR) for 6 months
Number of subjects: 21
Study: 12527158

Group type: EXPERIMENTAL
Intervention: Patient education and self-management intervention consisting of two 2-hour group sessions followed by 1-2 individual sessions by a nurse and a physiotherapist.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 78
Study: 11177273

Group type: EXPERIMENTAL
Intervention: Cisplatin (platinum derivative)
Number of subjects: 0
Study: 8634735

Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular (IM) ceftriaxone sodium
Number of subjects: 648

Group type: COMPARATOR
Intervention: 10-day oral amoxicillin and clavulanate potassium
Number of subjects: 648
Study: 2049686

Group type: EXPERIMENTAL
Intervention: Propranolol monotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem monotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem-nitrate combination
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isosorbide dinitrate added to either monotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Radionuclide ventriculography
Number of subjects: 24
Study: 6840166

Group type: EXPERIMENTAL
Intervention: Two well recognised treatment regimes
Number of subjects: 138